Apnimed indicated to open at $22 per share, IPO price $16

Apnimed, a pharmaceutical company focused on developing oral treatments for obstructive sleep apnea and related disorders, has drawn attention in the financial markets following reports that its shares opened at $22 apiece in its initial public offering (IPO), exceeding the initial IPO price of $16 per share. The company, founded in 2017 by Lawrence G. Miller and Luigi Taranto Montemurro, has raised a total of $224.52 million in funding across five rounds, with its most recent Series D round in April 2025 securing $16.5 million.

While the company has not officially confirmed the IPO price or opening share value, Forge Global notes that Apnimed has not yet filed for an IPO, and the reported figures may reflect secondary market activity or speculative trading. The company remains private and has not formally announced an IPO plan. Investors interested in pre-IPO opportunities or secondary market transactions can explore platforms like Forge to evaluate pricing and liquidity. As with any investment, potential investors are advised to conduct due diligence and consider market risks before making decisions.